CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?

I.M. Sechenov First Moscow State Medical University1,023 enrolled

Overview

Patients aged 18-89 with stable CAD and comorbidities receiving optimal medical treatment requiring PCI with iodinated contrast media. The aim of the study is to assess the prevalence of contrast-induced AKI in 2012-2013 and 2017 cohorts and to evaluate the potential risk factors of CI-AKI to better guide the prevention in patients of higher risk.

Study Type

OBSERVATIONAL

Enrollment

1,023

Conditions

Stable Angina Acute Kidney Injury Contrast-induced Nephropathy

Interventions

Iodinated contrast mediaPROCEDURE

Percutaneous coronary intervention with iodinated contest media

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent * Male and female patients 18 y. o. and older * Verified stable coronary artery disease (CAD) * Receiving optimal medical treatment and requiring percutaneous coronary intervention (PCI) with iodinated contrast media Exclusion Criteria: * Pregnancy, lactation * Conditions affecting the prognosis (kidney failure, liver failure, oncology) * Acute coronary syndrome (ACS) * Stroke * Contraindications to PCI * Therapy with nephrotoxic drugs during the enrolment which cannot be stopped * Refusal to sign the informed consent

Outcomes

Primary Outcomes

Overall mortality

Time frame: 5 years

Cardiovascular mortality

Time frame: 5 years

Myocardial infarction

Time frame: 5 years

Stroke

Time frame: 5 years

GI bleeding

Time frame: 5 years

CABG

CABG after PCI at enrolment

Time frame: 5 years

PCI

Repeat PCI after the enrolment

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.